Eli Lilly tirzepatide
Eli Lilly (NYSE:LLY) last month shared results from its Surpass-4 clinical trial that demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of its tirzepatide treatment when compared to titrated insulin glargine.
Tirzepatide, a novel, investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, integrates the actions of both incretins into a single molecule. Eli Lilly touts the treatment as a representation of a new class of medicines being studied for type 2 diabetes.
“Given the progressive nature of type 2 diabetes, evaluating the positive efficacy results we have seen with tirzepatide over longer periods of time is important,” Eli Lilly VP of Product Development Dr. Jeff Emmick said. “Throughout the length of Surpass-4, tirzepatide delivered robust improvements in blood glucose levels, significant weight loss and consistent safety results in adults with type 2 diabetes and increased cardiovascular risk.”
